ABBV vs PANW: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Palo Alto Networks, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Palo Alto Networks, Inc. · Technology
$174.41
-0.1% upside to fair value
Grade B
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+6.3%).
ABBV trades at a lower forward P/E
(83.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
PANW |
| Current Price |
$197.69 |
$174.41 |
| Fair Value Estimate |
$210.22 |
$174.18 |
| Upside to Fair Value |
+6.3%
|
-0.1%
|
| Market Cap |
$349.7B |
$118.9B |
| Forward P/E |
83.3x
|
94.6x
|
| EV / EBITDA |
23.4x
|
52.3x
|
| Price / Sales |
5.7x
|
12.0x
|
| Price / FCF |
18.7x
|
29.2x
|
| Revenue Growth YoY |
+10.0%
|
+14.9%
|
| Gross Margin |
70.2%
|
73.5%
|
| Operating Margin |
26.7%
|
14.4%
|
| Return on Equity |
-361.6%
|
15.5%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
3.42%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Palo Alto Networks, Inc. is a leading global cybersecurity company specializing in AI-driven security platforms with a strong recurring revenue base exceeding 80% of total revenue. The company benefits from a high gross margin of 73.5% and solid profitability with a net margin of 13.0%, supported by accelerating revenue growth of 14.9% and earnings growth of 61.6% in the most recent quarter. Unde…
Accumulation Zones
| Metric |
ABBV |
PANW |
| Zone Low |
$157.66 |
$130.63 |
| Zone High |
$178.69 |
$148.05 |
| In Buy Zone? |
No
|
No
|